Updated on 2024/11/25
学士（歯学） ( 2008.3 大阪大学 )
博士（理学） ( 2002.9 大阪大学 )
Master (Science) ( 1999.3 Osaka University )
学士（工学） ( 1997.3 姫路工業大学 )
Radiopharmaceutical Chemistry, Histochemistry
Life Science / Radiological sciences
Life Science / Human pathology
Osaka University Faculty of Dentistry School of Dentistry
- 2008.3
大阪大学大学院 理学研究科 化学
- 2002.9
Himeji Institute of Technology Faculty of Engineering
- 1997.3
Fukushima Medical University Department of Radiological Sciences, School of Health Sciences Professor
2021.4 - Now
Fukushima Medical University Fukushima Global Medical Science Center Advanced Clinical Research Center Professor
2021.4 - Now
Fukushima Medical University Hospital Medical Imaging Center Professor
2021.4 - Now
Kyoto Pharmaceutical University Center for Instrumental Analysis Associate Professor
2015.10 - 2021.3
Kumamoto University Pathology and experimental medicine Assistant Professor
2012.5 - 2015.9
RIKEN, Researcher Researcher
2008.4 - 2012.4
Institute for Protein Research, Osaka University, Researcher Institute for Protein Research
2002.10 - 2003.9
European Association of Nuclear Medicine
2023.1 - Now
日本放射線技術学会
2021.4 - Now
日本癌学会
2021.4 - Now
JAPAN SOCIETY OF HISTOCHEMISTRY AND CYTOCHEMISTRY
2013.4 - Now
THE JAPANESE SOCIETY OF PATHOLOGY
2013.4 - Now
Society of Radiopharmaceutical Sciences
2011.1 - Now
THE JAPANESE SOCIETY OF NUCLEAR MEDICINE
2008.4 - Now
THE PHARMACEUTICAL SOCIETY OF JAPAN
2008.4 - Now
The Japanese Peptide Society
1997.4 - Now
Hazardous Material Handler (first kind)
20150326
Dentist
20080425
Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model.
Kei Yaginuma, Kazuhiro Takahashi, Seiji Hoshi, Taiki Joho, Saki Shimoyama, Naoko Hasegawa, Koki Hasegawa, Songji Zhao, Naoyuki Ukon, Syunta Makabe, Satoru Meguro, Akifumi Onagi, Kanako Matsuoka, Soichiro Ogawa, Motohide Uemura, Tomoki Yamashita, Hiroyuki Suzuki, Tomoya Uehara, Yoshiyuki Kojima
European journal of nuclear medicine and molecular imaging 2024.10（ ISSN:1619-7070 ）
Tensho Yamao, Kenta Miwa, Yuta Kaneko, Noriyuki Takahashi, Noriaki Miyaji, Koki Hasegawa, Kei Wagatsuma, Yuto Kamitaka, Hiroshi Ito, Hiroshi Matsuda
Brain Sciences 14 ( 4 ) 406 - 406 2024.4（ ISSN:2076-3425 ）
Characterization of the expression of gastrin-releasing peptide and its receptor in the trigeminal and spinal somatosensory systems of Japanese macaque monkeys: Insight into humans.
Keiko Takanami, Takumi Oti, Yasuhisa Kobayashi, Koki Hasegawa, Takashi Ito, Naoaki Tsutsui, Yasumasa Ueda, Earl Carstens, Tatsuya Sakamoto, Hirotaka Sakamoto
The Journal of comparative neurology 530 ( 16 ) 2804 - 2819 2022.6（ ISSN:0021-9967 ）
Development of a phoswich detector composed of ZnS(Ag) and YAP(Ce) for astatine-211 imaging
Seiichi Yamamoto, Naoyuki Ukon, Kohshin Washiyama, Koki Hasegawa, Kei Kamada, Masao Yoshino, Akira Yoshikawa
Radiation Measurements 153 106734 - 106734 2022.3（ ISSN:1350-4487 ）
Discussion on Translational Research of Drug Product for Targeted Alpha Therapy-Part 8-Discussion on Targeted Alpha Therapy for Viral Infection
矢野恒夫, 淵上剛志, 高橋豊, 角永悠一郎, 長谷川功紀, 加藤弘樹, 渡部直史, 樺山一哉, 山村朝雄, 佐藤達彦, 佐藤達彦, 平林容子, 藤井博史, 米倉義晴, 深瀬浩一
Pharm Tech Japan 38 ( 13 ) 2022（ ISSN:0910-4739 ）
矢野恒夫, 角永悠一郎, 樺山一哉, 加藤弘樹, 高橋豊, 山村朝雄, 長谷川功紀, 佐藤達彦, 佐藤達彦, 淵上剛志, 渡部直史, 巽光朗, 平林容子, 藤井博史, 米倉義晴, 深瀬浩一
Pharm Tech Japan 38 ( 2 ) 281 - 289 2022（ ISSN:0910-4739 ）
アルファ線核医学治療のための薬剤開発の考察(その6) 標的分子・創薬化学の重要性(後編)
矢野 恒夫, 長谷川 功紀, 石井 明子, 渡部 直史, 巽 光朗, 角永 悠一郎, 樺山 一哉, 深瀬 浩一, 米倉 義晴, 平林 容子, 佐藤 達彦, 藤井 博史
PHARM TECH JAPAN 37 ( 14 ) 2483 - 2493 2021.11（ ISSN:0910-4739 ）
アルファ線核医学治療のための薬剤開発の考察(その6) 標的分子・創薬化学の重要性(前編)
矢野 恒夫, 長谷川 功紀, 石井 明子, 渡部 直史, 巽 光朗, 角永 悠一郎, 樺山 一哉, 深瀬 浩一, 米倉 義晴, 平林 容子, 佐藤 達彦, 藤井 博史
PHARM TECH JAPAN 37 ( 11 ) 1921 - 1930 2021.8（ ISSN:0910-4739 ）
アルファ線核医学治療のための薬剤開発の考察(その5) IAEA Technical Meeting報告 α線核種並びにTAT薬剤の最新動向
矢野 恒夫, 長谷川 功紀, 山村 朝雄, 渡部 直史, 巽 光朗, 佐藤 達彦, 角永 悠一郎, 樺山 一哉, 深瀬 浩一, 平林 容子, 藤井 博史, 米倉 義晴
医薬品医療機器レギュラトリーサイエンス 52 ( 2 ) 85 - 106 2021.2（ ISSN:1884-6076 ）
Facile synthesis of 2-deoxy-2-[18 F]fluorosorbitol using sodium borohydride on aluminum oxide.
Koki Hasegawa, Kazuhiro Koshino, Takahiro Higuchi
Journal of labelled compounds & radiopharmaceuticals 64 ( 1 ) 40 - 46 2021.1（ ISSN:0362-4803 ）
Tsuneo Yano, Koki Hasegawa, Tatsuhiko Sato, Mitsuaki Tatsumi, Tadashi Watabe, Yuichiro Kadonaga, Kazuya Kabayama, Koichi Fukase, Akiko Hachisuka, Yoko Hirabayashi, Hirofumi Fujii, Yoshiharu Yonekura
RADIOISOTOPES 69 ( 10 ) 329 - 340 2020.10（ ISSN:1884-4111 ）
Takashi Ohgita, Yuki Takechi-Haraya, Keisuke Okada, Saki Matsui, Misaki Takeuchi, Chihiro Saito, Kazuchika Nishitsuji, Kenji Uchimura, Ryuji Kawano, Koki Hasegawa, Kumiko Sakai-Kato, Kenichi Akaji, Ken-Ichi Izutsu, Hiroyuki Saito
Biochimica et biophysica acta. Biomembranes 1862 ( 10 ) 183403 - 183403 2020.10（ ISSN:00052736 ）
Koki Hasegawa, Rika Maedomari, Younosuke Sato, Kumiko Gotoh, Shinji Kudoh, Akihiro Kojima, Seiji Okada, Takaaki Ito
ChemMedChem 15 ( 18 ) 1699 - 1705 2020.9（ ISSN:18607179 ）
アルファ線核医学治療のための薬剤開発の考察(その4) First-in-Human臨床に向けた要件
矢野 恒夫, 長谷川 功紀, 佐藤 達彦, 巽 光朗, 渡部 直史, 藤井 博史, 角永 悠一郎, 樺山 一哉, 深瀬 浩一, 米倉 義晴, 蜂須賀 暁子, 平林 容子
医薬品医療機器レギュラトリーサイエンス 51 ( 8 ) 364 - 377 2020.8（ ISSN:1884-6076 ）
アルファ線核医学治療のための薬剤開発の考察(その3)
矢野 恒夫, 長谷川 功紀, 角永 悠一郎, 樺山 一哉, 小田 敬, 上野 悟史, 蜂須賀 暁子, 平林 容子, 深瀬 浩一
医薬品医療機器レギュラトリーサイエンス 50 ( 12 ) 749 - 763 2019.12（ ISSN:1884-6076 ）
国内未承認RI内用療法に関する海外動向ならびに国内導入に向けた臨床サイドから見たニーズ・問題点に関する調査研究
福島 和人, 高野 祥子, 長谷川 功紀, 野上 宗伸, 日向 信之, 樋口 隆弘
核医学 56 ( 1 ) 77 - 79 2019.6（ ISSN:0022-7854 ）
Takashi Ohgita, Yuki Takechi-Haraya, Ryo Nadai, Mana Kotani, Yuki Tamura, Karin Nishikiori, Kazuchika Nishitsuji, Kenji Uchimura, Koki Hasegawa, Kumiko Sakai-Kato, Kenichi Akaji, Hiroyuki Saito
Biochimica et biophysica acta. Biomembranes 1861 ( 3 ) 541 - 549 2019.3（ ISSN:0005-2736 ）
アルファ線核医学治療のための薬剤開発の考察(その2)
矢野 恒夫, 長谷川 功紀, 佐藤 達彦, 蜂須賀 暁子, 深瀬 浩一, 平林 容子
医薬品医療機器レギュラトリーサイエンス 50 ( 3 ) 122 - 134 2019.3（ ISSN:1884-6076 ）
アルファ線核医学治療のための薬剤開発の考察(その1)
矢野 恒夫, 長谷川 功紀, 蜂須賀 暁子, 深瀬 浩一, 平林 容子
医薬品医療機器レギュラトリーサイエンス 49 ( 10 ) 676 - 684 2018.10（ ISSN:1884-6076 ）
Relationship between the fluorescence intensity of rhodamine-labeled orexin A and the calcium responses in cortical neurons: An in vivo two-photon calcium imaging study.
Saori Ohtani, Satoshi Fujita, Koki Hasegawa, Hiromasa Tsuda, Morio Tonogi, Masayuki Kobayashi
Journal of pharmacological sciences 138 ( 1 ) 76 - 82 2018.9（ ISSN:1347-8613 ）
Expression of Draxin in Lung Carcinomas.
Younosuke Sato, Akira Matsuo, Shinji Kudoh, Liu Fang, Koki Hasegawa, Yohei Shinmyo, Takaaki Ito
Acta histochemica et cytochemica 51 ( 1 ) 53 - 62 2018.2（ ISSN:0044-5991 ）
Koki Hasegawa, Emi Kawachi, Yoshinari Uehara, Tsuyoshi Yoshida, Satoshi Imaizumi, Masahiro Ogawa, Shin-Ichiro Miura, Keijiro Saku
Journal of labelled compounds & radiopharmaceuticals 60 ( 1 ) 55 - 61 2017.1（ ISSN:0362-4803 ）
Koki Hasegawa, Shinji Kudoh, Takaaki Ito
PloS one 12 ( 2 ) e0172030 - e0172030 2017（ ISSN:1932-6203 ）
Masako Shimamoto, Kumiko Gotoh, Koki Hasegawa, Akihiro Kojima
Molecular imaging and biology 18 ( 4 ) 500 - 9 2016.8（ ISSN:1536-1632 ）
Noriyasu Kamei, Tomotaka Shingaki, Yousuke Kanayama, Misa Tanaka, Riyo Zochi, Koki Hasegawa, Yasuyoshi Watanabe, Mariko Takeda-Morishita
Molecular pharmaceutics 13 ( 3 ) 1004 - 11 2016.3（ ISSN:1543-8384 ）
Akihiro Kojima, Kumiko Gotoh, Masako Shimamoto, Koki Hasegawa, Seiji Okada
Annals of nuclear medicine 30 ( 2 ) 169 - 75 2016.2（ ISSN:0914-7187 ）
Notch1 controls cell chemoresistance in small cell lung carcinoma cells.
Wael Abdo Hassan, Ryoji Yoshida, Shinji Kudoh, Hiroki Kameyama, Koki Hasegawa, Kanako Niimori-Kita, Takaaki Ito
Thoracic cancer 7 ( 1 ) 123 - 8 2016.1（ ISSN:1759-7706 ）
Kosuke Fujino, Yamato Motooka, Wael A Hassan, Mohamed O Ali Abdalla, Yonosuke Sato, Shinji Kudoh, Koki Hasegawa, Kanako Niimori-Kita, Hironori Kobayashi, Ichiro Kubota, Joeji Wakimoto, Makoto Suzuki, Takaaki Ito
The American journal of pathology 185 ( 12 ) 3164 - 77 2015.12（ ISSN:0002-9440 ）
Notch1 controls cell invasion and metastasis in small cell lung carcinoma cell lines.
Wael Abdo Hassan, Ryoji Yoshida, Shinji Kudoh, Koki Hasegawa, Kanako Niimori-Kita, Takaaki Ito
Lung cancer (Amsterdam, Netherlands) 86 ( 3 ) 304 - 10 2014.12（ ISSN:0169-5002 ）
Notch1 signaling controls cell proliferation, apoptosis and differentiation in lung carcinoma
Hassan Wael, Ryoji Yoshida, Shinji Kudoh, Kohki Hasegawa, Kanako Niimori-Kita, Takaaki Ito
Lung Cancer 85 ( 2 ) 131 - 140 2014.8（ ISSN:0169-5002 ）
Bromodeoxyuridine (BrdU)-label-retaining cells in mouse terminal bronchioles
Kameyama, H., Kudoh, S., Udaka, N., Kagayama, M., Hassan, W., Hasegawa, K., Niimori-Kita, K., Ito, T.
Histology and Histopathology 29 ( 5 ) 659 - 668 2014（ ISSN:0213-3911 ）
Kanako Niimori-Kita, Kiyoshi Ogino, Sayaka Mikami, Shinji Kudoh, Daikai Koizumi, Noritaka Kudoh, Fumiko Nakamura, Masahiro Misumi, Tadasuke Shimomura, Koki Hasegawa, Fumihiko Usui, Noriyuki Nagahara, Takaaki Ito
FEBS open bio 4 746 - 54 2014（ ISSN:2211-5463 ）
Takeo Sako, Koki Hasegawa, Mie Nishimura, Yousuke Kanayama, Yasuhiro Wada, Emi Hayashinaka, Yilong Cui, Yosky Kataoka, Michio Senda, Yasuyoshi Watanabe
Biochemical and biophysical research communications 442 ( 1-2 ) 79 - 84 2013.12（ ISSN:0006-291X ）
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
Kenji Tamura, Hiroaki Kurihara, Kan Yonemori, Hitoshi Tsuda, Junko Suzuki, Yuzuru Kono, Natsuki Honda, Makoto Kodaira, Harukaze Yamamoto, Mayu Yunokawa, Chikako Shimizu, Koki Hasegawa, Yousuke Kanayama, Satoshi Nozaki, Takayuki Kinoshita, Yasuhiro Wada, Shusaku Tazawa, Kazuhiro Takahashi, Yasuyoshi Watanabe, Yasuhiro Fujiwara
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 54 ( 11 ) 1869 - 75 2013.11（ ISSN:0161-5505 ）
Comparison of 68Ga and 64Cu for Molecular Imging of Atherosclerosis using apo A-I mimetic Peptide FAMP
Eiji Yahiro, Yoshinari Uehara, Emi Kawachi, Koki Hasegawa, Setsuko Ando, Shin-ichiro Miura, Keijiro Saku
CIRCULATION 128 ( 22 ) 2013.11（ ISSN:0009-7322 ）
Ikuko Nakamura, Koki Hasegawa, Yasuhiro Wada, Tetsuaki Hirase, Koichi Node, Yasuyoshi Watanabe
Biochemical and Biophysical Research Communications 433 ( 1 ) 47 - 51 2013.3（ ISSN:0006-291X ）
Emi Kawachi, Yoshinari Uehara, Koki Hasegawa, Eiji Yahiro, Setsuko Ando, Yasuhiro Wada, Tsuneo Yano, Hiroaki Nishikawa, Masashi Shiomi, Shin ichiro Miura, Yasuyoshi Watanabe, Keijiro Saku
Circulation Journal 77 ( 6 ) 1482 - 1489 2013（ ISSN:1346-9843 ）
Cu-64-DOTA-trastuzumab-PET imaging in patients with HER2-positive breast cancer
Kenji Tamura, Hiroaki Kurihara, Kan Yonemori, Kazuhiro Takahashi, Yasuhiro Wada, Koki Hasegawa, Fumiaki Koizumi, Hitoshi Tsuda, Makoto Kodaira, Mayu Yunokawa, Chikako Shimizu, Masashi Ando, Yasuyoshi Watanabe, Yasuhiro Fujiwara
JOURNAL OF CLINICAL ONCOLOGY 30 ( 15 ) 2012.5（ ISSN:0732-183X ）
The feasibility study of 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer
Yonemori, Kan, Tamura, Kenji, Kurihara, Hiroaki, Kono, Yuzuru, Arai, Yasuaki, Wada, Yasuhiro, Takahashi, Kazuhiro, Hasegawa, Koki, Watanabe, Yasuyoshi, Fujiwara, Yasuhiro
JOURNAL OF NUCLEAR MEDICINE 53 2012.5（ ISSN:0161-5505 ）
抗体医薬及び核酸医薬などバイオPET薬剤の安全性評価のための考察
矢野 恒夫, 豊田 浩士, 長谷川 功紀, 野崎 聡, 中村 郁子, 片岡 洋祐
医薬品医療機器レギュラトリーサイエンス 43 ( 2 ) 116 - 122 2012.2（ ISSN:1884-6076 ）
Novel System for the Molecular Imaging of Atherosclerotic Plaque with Ga-68-DOTA-ApoA-I Mimetic Peptide (-FAMP)
Eiji Yahiro, Yoshinari Uehara, Koki Hasegawa, Emi Kawachi, Tsuneo Yano, Yasuyoshi Watanabe, Shin-ichiro Miura, Keijiro Saku
CIRCULATION 124 ( 21 ) 2011.11（ ISSN:0009-7322 ）
理研CMISにおける64Cu-DOTA-Trastuzumab注射液の治験薬GMP製造への取り組み
田沢 周作, 長谷川 功紀, 高橋 和弘, 矢野 恒夫, 渡辺 恭良
PHARM TECH JAPAN 27 ( 3 ) 431 - 440 2011.3（ ISSN:0910-4739 ）
Current Practice of producing Cu-64-DOTA-Trastuzumab Injections in RIKEN CMIS according to GMP for Investigational Products
Shusaku Tazawa, Koki Hasegawa, Yousuke Kanayama, Riyo Zochi, Yoko Morimoto, Kazutaka Hayashi, Akiko Tachibana, Kazuhiro Takahashi, Tsuneo Yano, Yasuyoshi Watanabe
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS 54 S160 - S160 2011（ ISSN:0362-4803 ）
Katsunori Tanaka, Eric R.O. Siwu, Kaori Minami, Koki Hasegawa, Satoshi Nozaki, Yousuke Kanayama, Koichi Koyama, Weihsu C. Chen, James C. Paulson, Yasuyoshi Watanabe, Koichi Fukase
Angewandte Chemie - International Edition 49 ( 44 ) 8195 - 8200 2010.10（ ISSN:1433-7851 ）
Noriyasu Kamei, M. Morishita Mariko, Yousuke Kanayama, Koki Hasegawa, Mie Nishimura, Emi Hayashinaka, Yasuhiro Wada, Yasuyoshi Watanabe, Kozo Takayama
Journal of Controlled Release 146 ( 1 ) 16 - 22 2010.8（ ISSN:0168-3659 ）
長谷川 功紀, 渡辺 恭良
腫瘍内科 6 ( 1 ) 86 - 92 2010.7（ ISSN:1881-6568 ）
First Positron Emission Tomography (PET) Imaging of Glycoproteins and Glycodendrimers by Efficient Chemical Labeling with [Ga-68]-DOTA
Katsunori Tanaka, Eric Richard Oktavianus Siwu, Kaori Minami, Koki Hasegawa, Yousuke Kanayama, Hiroshi Mizuma, Yasuhiro Wada, Yasuyoshi Watanabe, Koichi Fukase
GLYCOBIOLOGY 18 ( 11 ) 981 - 981 2008.11（ ISSN:0959-6658 ）
Katsunori Tanaka, Tatsuro Masuyama, Koki Hasegawa, Tsuyoshi Tahara, Hiroshi Mizuma, Yasuhiro Wada, Yasuyoshi Watanabe, Koichi Fukase
Angewandte Chemie - International Edition 47 ( 1 ) 102 - 105 2008（ ISSN:1433-7851 ）
Synthesis of an olefin-containing cyclic peptide using the solid-phase Horner-Emmons reaction
Jeong Kyu Bang, Koki Hasegawa, Toru Kawakami, Saburo Aimoto, Kenichi Akaji
Tetrahedron Letters 45 ( 1 ) 99 - 102 2004.1（ ISSN:0040-4039 ）
Preparation of phosphopeptide thioesters by Fmoc- and Fmoc(2-F)-solid phase synthesis
Koki Hasegawa, Yin Lin Sha, Jeong Kyu Bang, Toru Kawakami, Kenichi Akaji, Saburo Aimoto
Letters in Peptide Science 8 ( 3-5 ) 277 - 284 2001.5（ ISSN:0929-5666 ）
Toru Kawakami, Koki Hasegawa, Kenta Teruya, Kenichi Akaji, Masataka Horiuchi, Fuyuhiko Inagaki, Yasuyuki Kurihara, Seiichi Uesugi, Saburo Aimoto
Journal of Peptide Science 7 ( 9 ) 474 - 487 2001（ ISSN:1075-2617 ）
Polypeptide synthesis using an expressed peptide as a building block via the thioester method
Toru Kawakami, Koki Hasegawa, Kenta Teruya, Kenichi Akaji, Masataka Horiuchi, Fuyuhiko Inagaki, Yasuyuki Kurihara, Seiichi Uesugi, Saburo Aimoto
Tetrahedron Letters 41 ( 15 ) 2625 - 2628 2000.4（ ISSN:0040-4039 ）
Synthesis of a phosphorylated polypeptide by a thioester method
Toru Kawakami, Koki Hasegawa, Saburo Aimoto
Bulletin of the Chemical Society of Japan 73 ( 1 ) 197 - 203 2000.1（ ISSN:0009-2673 ）
Handbook of in vivo chemistry in mice : from lab to living system
Tanaka, Katsunori, Vong, Kenward
Wiley-VCH 2020 （ ISBN:9783527344321 ）
医療・診断をささえるペプチド科学 : 再生医療・DDS・診断への応用
平野, 義明
シーエムシー出版 2017.10 （ ISBN:9784781312675 ）
次世代ペプチド医薬創製
赤路, 健一
メディカルドゥ 2014.8 （ ISBN:9784944157686 ）
創薬研究への分子イメージング応用
佐治, 英郎
メディカルドゥ 2010.12 （ ISBN:9784944157488 ）
創薬技術の革新 : マイクロドーズからPET分子イメージングへの新展開
杉山, 雄一, 山下, 伸二, 栗原, 千絵子
メディカルドゥ 2010.10 （ ISBN:9784944157808 ）
上皮成長因子受容体(EGFR)を標的とした細胞溶解薬剤の開発
日本薬学会第142年会
ポリプロリンヘリックスIIヘリックス構造によるアルギニンペプチドの細胞膜透過性の亢進
日本薬学会第140年会
67Ga標識Reactive Black 5を利用した炎症巣のSPECTイメージング
日本薬学会第140年会
タモキシフェン誘導体を用いた肺がんのリガンド誘導体染色
第60回日本組織細胞化学会総会・学術集会
ApoE由来アルギニンペプチドの細胞膜透過における糖鎖依存性の評価
日本薬学会第139年会
両親媒性環状ペプチドの細胞膜透過機構解明に向けたペプチドの合成
日本薬学会第139年会
低分子リガンドを用いたエストロゲン受容体検出法の開発
第59回日本組織細胞化学会総会・学術集会
肺癌における新しいガイダンス分子であるドラキシンについて
第108回日本病理学会総会
リガンド誘導体を用いた受容体検出法の開発
第123回日本解剖学会総会・全国学術集会
エストラジオール誘導体を用いたその受容体検出法の開発
日本薬学会第138年会
新規両親媒性アルギニンペプチドの細胞膜透過性の評価
日本薬学会第138年会
リガンド誘導体染色によるソマトスタチン受容体の検出法
第56 回日本臨床細胞学会秋期大会
アポE糖鎖結合ドメインに基づく両親媒性膜透過ペプチドの設計
膜シンポジウム
抗体リポソームによる選択的BPA取込み増強のためのアミノ酸トランスポーターLAT1遺伝子導入技術の開発
第14回日本中性子補足療法学会学術大会
リガンド誘導体染色法を用いたKisspeptin Receptor(KISS1R)の検出検討
第58回日本組織細胞化学会総会・学術集会
Synthesis of 67Ga-labeled Kisspeptin10 and in vivo evaluation for medullary thyroid carcinoma imaging
22nd International Symposium on Radiopharmaceutical Sciences
Visualization of cancer metastasis with radiolabeled ligands of Kiss1 receptors by SPECT
26th Federation of Asian Pharmaceutical Associations Congress
Kiss1受容体発現腫瘍スクリーニングと67Ga-DOTA-Kisspeptin10を用いたSPECTイメージング
第56回日本核医学会学術総会
CCK-8誘導体を用いたホルマリン固定パラフィン包埋切片上中のコレシストキニン受容体検出
第53回ペプチド討論会
リガンド誘導体染色法を用いたコレシストキニン受容体の検出
第57回日本組織細胞化学会総会・学術集会
リガンド誘導体を用いた受容体染色剤の開発
日本薬学会年会第136年会
生体内にて標的組織に指向する放射標識化合物およびその利用
膵臓内分泌細胞用指示薬、及びその利用
DOTAの導入法
新規ヘキサトリエン−β−カルボニル化合物
新規ヘキサトリエン−β−カルボニル化合物
Development of alpha-ray microdosimetry at the cellular level
Grant number：23K27554 2023.4 - 2026.3
Grant-in-Aid for Scientific Research (B)
Grant amount：\18850000 （ Direct Cost: \14500000 、 Indirect Cost：\4350000 ）
Genetic basis of individual differences in itch sensitivity using mouse strain differences
Grant number：22K06058 2022.4 - 2025.3
Grant-in-Aid for Scientific Research (C)
Grant amount：\4290000 （ Direct Cost: \3300000 、 Indirect Cost：\990000 ）
Signal molecules of ASCL1, a lineage-specific transcription factor for small cell carcinoma of the lung
Grant number：20H03691 2020.4 - 2024.3
Grant-in-Aid for Scientific Research (B)
Grant amount：\17680000 （ Direct Cost: \13600000 、 Indirect Cost：\4080000 ）
Grant number：17K08749 2017.4 - 2020.3
Grant-in-Aid for Scientific Research (C)
Hasegawa Koki
Grant amount：\4680000 （ Direct Cost: \3600000 、 Indirect Cost：\1080000 ）
It is difficult to produce good quality antibodies. Occasionally, the reproducibility of an experiment may not be achieved due to the quality of the antibody. To overcome these problems, we prepared low molecular-weighted ligand agents that can be constant quality for detection. The method using low molecular-weighted ligand agents alternative to antibodies was named Western ligand blot and ligand derivertive stain, respectively. In this study, tamoxifen derivative was used to detect estrogen receptor. The estrogen receptor was successfully detected by the Western ligand blot. We have also successfully stained pathological sections of lung adenocarcinoma and lung squamous cell carcinoma with ligand derivaertive stain.
Grant number：16K15459 2016.4 - 2018.3
Grant-in-Aid for Challenging Exploratory Research
Ito Takaaki, MATSUO Akira, SHINMYO Yohei, HASEGAWA Koki
Grant amount：\3380000 （ Direct Cost: \2600000 、 Indirect Cost：\780000 ）
The axon guidance molecule-receptor system works not only in neural network formation, and but also in cancer cell proliferation and apoptosis. Draxin and Netrin1 share their receipt, DCC and Neogenin. This study was done to elucidate the significance of the guidance molecule-receptor system in lung cancer cell proliferation and survival. Western blotting and immunohistochemical studies revealed that small cell lung cancer and non-small cell lung cancer express these molecules. Though gene knockdown and over-expression studies using small cell lung cancer cell lines, using non-small cell lung cancer cell lines, we demonstrated that the system works in lung cancer cell proliferation and survival. And, it is suggested that Draxin could interact directly with Netrin1 in cancer cell proliferation.
Grant number：16K15783 2016.4 - 2018.3
Grant-in-Aid for Challenging Exploratory Research
KOBAYASHI Masayuki
Grant amount：\3380000 （ Direct Cost: \2600000 、 Indirect Cost：\780000 ）
Neural responses to a ligand exhibit a wide variation from neuron to neuron, however, underling mechanisms of the response variation remains unclear. One possible mechanism is a variation of the number of receptors expressed in each neural membrane. To examine this hypothesis, we synthesized rhodamine-labeled orexin A compound, which enabled us to quantify the amount of orexin binding to orexin receptors, OX1 and OX2. Application of rhodamine-labeled orexin A to the cortical surface heterogeneously increased both the intensity of the rhodamine fluorescence and [Ca2+]i. We classified neurons into high- and low-responding neurons based on the peak amplitude of [Ca2+]i increase. Intensity of the rhodamine fluorescence in high-responding neurons was significantly larger than that in low-responding neurons. These results suggest that a part of mechanisms for varying neural responses including [Ca2+]i increases are the diversity of the amount of receptor expression in the neural membrane.
Grant number：15K21774 2016 - 2019
Fund for the Promotion of Joint International Research (Home-Returning Researcher Development Research)
HIGUCHI Takahiro, FUKUSHIMA Kazuhito, KIMURA Hiroyuki, HASEGAWA Koki, FUKUCHI Kazuki, SAITO Shigeyoshi, FUKUSHIMA Kenji, ZENIYA Tsutomu, NAKAJIMA Kenichi, TAKI Junichi, YAMAYA Taiga, TORIUMI Fujio, SHIOYA Kyoko
Grant amount：\57200000 （ Direct Cost: \44000000 、 Indirect Cost：\13200000 ）
This research project aims to develop a new PET molecular imaging technology and establish a new treatment strategy for patients with heart failure. The principle investigator (PI) has set up a new research base in Japan as the director of the bio-medical imaging department of the National Cardiovascular Research Center. While transferring various knowledge and technologies to Japanese researchers, we have created an environment that enables to conduct state of the art PET imaging research. Since last year, PI has been a professor at Okayama University and has been accelerating the exchange of technology and young researchers with various countries. Furthermore, among the new tracer technology developed in this research project, we have identified multiple tracer candidates that are considered to be highly effective in diagnosing heart failure and will continue further study for clinical application.
Development of multimodal theranostics tracer for personalized medicine in immuno-oncology
Grant number：15K08698 2015.4 - 2018.3
Grant-in-Aid for Scientific Research (C)
Kubo Hitoshi, NAKAMURA Michihiro, HASEGAWA Koki
Grant amount：\4810000 （ Direct Cost: \3700000 、 Indirect Cost：\1110000 ）
In this study, multimodal theranostics tracer using nano particle has been developed to use for diagnostication with CT, MRI, SPECT, PET, and also treatment with unsealed source radiotherapy in immuno-oncology. The methods for labeling antibody and radioisotope to the organosilica nanoparticle that contained fluorescent dye were developed. The differences of the pharmacokinetics of the tracer in the mice that had transplanted different type of the tumor cell were observed. It was indicated that antibody imaging has been succeeded using this developed method. In spite of this observation, wholebody imaging using SPECT and fluorecent imaging were not succeeded due to low sensitivity. Additional technical development for higher sensitivity will be required to apply this tracer for clinical use in the future.
Establishment of novel immunoPET/MRI using 64cU
Grant number：15K15456 2015.4 - 2018.3
Grant-in-Aid for Challenging Exploratory Research
Honda Hiroshi
Grant amount：\3640000 （ Direct Cost: \2800000 、 Indirect Cost：\840000 ）
In this study, we aim to establish antibody labeled PET (immunoPET) by labeling various kinds of antibodies including molecular targeted drugs using 64Cu which is a positron nuclide having a relatively long half life. Until now, we have completed the preparation for starting the synthesis by constructing the target system, implementing it in the cyclotron, and installing the metal nuclide generation device in the hot laboratory through joint development with the manufacturer. For the procurement of 64Ni as a raw material and the plating process of Ni on a gold target, work procedures are established and phantom experiments are carried out using the obtained 64Cu. The current problem is that the discharge rate of 64 Cu to the waste liquid is higher than the final yield. We are planning to adjusted dispensing column.
Grant number：26460453 2014.4 - 2017.3
Grant-in-Aid for Scientific Research (C)
Hasegawa Koki
Authorship：Principal investigator Grant type：Competitive
Grant amount：\5070000 （ Direct Cost: \3900000 、 Indirect Cost：\1170000 ）
We have been focusing on Kiss1 receptor (Kiss1R), which might be a key role factor of metastasis, and developing the stainer and SPECT probe for Kiss1R. Kisspeptin10 is a ligand of Kiss1R and consists of10 amino acid residues. Kisspeptin10 was derivatized as the stainer and SPECT probe. Kisspeptin10 stainer was visualized the localization of Kiss1R in pathological tissue sections of lung adenocarcinoma, lung squamous cell carcinoma, small cell lung carcinoma and medullary thyroid carcinoma. Next, Kisspeptin10 was labelled with 67Ga. 67Ga-labeled Kisspeptin10 was injected to the mouse bearing medullary thyroid carcinoma cells to take the SPECT/CT. As the result, Kisspeptin10 was highly accumulated in carcinoma. We concluded that the stainer and SPECT probe for Kiss1R were developed successfully.
Mechanisms on genesis of combined type small cell carcinoma; a study focusing on Notch signaling
Grant number：25460439 2013.4 - 2016.3
Grant-in-Aid for Scientific Research (C)
Ito Takaaki, NIIMORI Kanako, HASEGAWA Koki
Grant amount：\5070000 （ Direct Cost: \3900000 、 Indirect Cost：\1170000 ）
Combined type of small cell lung carcinoma (SCLC) has both small cell cancer and non-small cell carcinoma components such as adenocarcinoma and squamous cell carcinoma, which are positive for NOTCH1 and negative for INSM1, one of neuroendocrine transcription factor. Mechanisims of NOTCH1 expression in the process of genesis of the combined type SCLC could be epigenetically regulated. NOTCH1-negative classical SCLC cell lines expressed NOTCH1 after trichostatin A treatment, and Chip assay showed that level of acetylated histone H3 surrounding Notch1 promoter region was low in them. Taken together, genesis of combined type SCLC requires NOTCH expression, which could be regulated by histone modification.
Grant number：23602016 2011.4 - 2015.3
Grant-in-Aid for Scientific Research (C)
SAKO Takeo, HASEGAWA Koki, KATAOKA Yousuke, CUI Yilong, TOYODA Hiroshi, NISHIMURA Mie, HAYASHINAKA Emi, WADA Yasuhiro
Grant amount：\4160000 （ Direct Cost: \3200000 、 Indirect Cost：\960000 ）
Pancreatic beta cell mass is thought to be useful biomarker for diabetes, but so far the only way to measure beta cell mass is the biopsy, which is so invasive that it cannot be done before diagnosis nor so many times even after diagnosis. Therefore, non-invasive method to quantify the beta cell mass is needed.
Positron Emission Tomograpy (PET) has good sensitivity and quantificapability, compared with other imaging modalities. Our goal is to establish non-invasive measurement of beta cell mass with PET. We performed PET studies with radiolabeled somatostatin analogs and revealed that they were good candidates for evaluation of beta cell mass.
Grant number：23791465 2011 - 2013
Grant-in-Aid for Young Scientists (B)
HASEGAWA Koki
Authorship：Principal investigator Grant type：Competitive
Grant amount：\4160000 （ Direct Cost: \3200000 、 Indirect Cost：\960000 ）
We prepared NODAGA-EGF as a molecular probe and set up the molecular imaging device in Kumamoto University. EGF, which consists of 53 amino acid residues, was synthesized by Fmoc solid-phase method. After elongation of peptide chain, NODAGA(tBu)3 was introduced at N-terminus. Fully protected peptide resin was treated in TFA solution to cleave from resin and remove protection groups. After HPLC purification, disulfide bonds were formed to give the labeling precursor. Next, to perform molecular imaging study, SPECT/CT was set up. We established a method to form stable complex with Ga-67 via DOTA chelator. SPECT device was checked the accuracy of quantification and image resolution. SPECT imaging using 67Ga-DOTA-octreotate was carried out on the mouse implanted with small cell lung tumor cell (H69). As the result, we could observe the accumulation of the Ga-67 in H69 tumor.
Pancreatic β cell imaging using 64Cu- or 68Ga-labeled Exendin-4
Grant number：21791228 2009 - 2010
Grant-in-Aid for Young Scientists (B)
HASEGAWA Koki
Authorship：Principal investigator Grant type：Competitive
Grant amount：\3510000 （ Direct Cost: \2700000 、 Indirect Cost：\810000 ）
64Cu- or 68Ga-labeled Exendin-4 was synthesized and PET imagings were performed. DOTA-Exendin-4 was synthesized by thioester method. N-terminal segment with DOTA moiety [DOTA-Exendin(1-4)] was condensed with C-terminal segment [Exendin-4(5-39)] to give DOTA-Exendin4. Obtained DOTA-Exendin-4 could be labeled with Ga-68. 64Cu-labeled Exendin-4 was synthesized utilizing Cu binding motif (ATCUN). Exendin-4 with ATCUN motif was could be labeled with Cu-64. PET imagings and biodistribution studies were performed. Biodistribution studies revealed the high accumulation in liver and pancreas. The results of PET imaging, the accumulation of pancreas was determined within 30min after injection. Over 30min, metabolized probe was secreted into the bile. So the accumulation of pancreas could not be distinguished from the intestine including the bile.
大学模擬講義＠宮城県立石巻高校
2021.10
